$CL

Colgate-Palmolive (NYSE: CL) CEO gets new stock awards

Colgate-Palmolive (CL) granted its CEO, Noel R. Wallace, 205,197 stock options and 29,649 restricted stock units on September 16, 2026. The options have an exercise price of $87.02 and expire in 2036, vesting over three years. The RSUs vest in equal installments over three years. Wallace's total direct and indirect holdings now exceed 487,000 shares.

Original reporting
Published Sep 18, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CL
Neutral
medium confidence
Mentioned
$CL
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLNeutralLow
01

Why it matters

The award modestly raises insider ownership but is unlikely to drive significant stock movement.

02

Market read

A routine insider compensation filing with limited trading relevance.

03

What to watch

Potential tax implications for the CEO and future dilution if options are exercised.

Relevance 4/10Novelty 4/10Timing: post‑market September 16, 2026

Background

Colgate‑Palmolive regularly files Form 8‑K disclosures for executive compensation.

Company-level read

Ticker impact

$CLNeutralMedium confidence
Context

CEO Noel R. Wallace was granted 205,197 stock options and 29,649 RSUs on September 16, 2026, increasing his direct and indirect holdings.

Expected impact

Limited short‑term price impact; potential slight upside if market views the grant as a positive signal.

Evidence & confidence

Grants are routine compensation events; the size is modest relative to market cap, so any price move is likely muted.

Market effects

Minimal impact on consumer staples sector; similar compensation practices are common.

U.S. market only; no broader regional effect.

Low; the news is company‑specific and does not affect global markets.

Counterpoint

The grant could be seen as a defensive move, indicating management expects challenges ahead.

Key entities

  • Noel R. Wallace

    Chairman, President & CEO of Colgate‑Palmolive

Related articles

$CLMed

Piper Sandler cuts Colgate-Palmolive stock price target on cost pressures

Piper Sandler reduced its price target for Colgate-Palmolive (CL) to $95 from $98, citing cost pressures from elevated oil prices and inventory headwinds. The firm maintained an Overweight rating and a 2026 EPS estimate of $3.85, but lowered its 2027 EPS estimate to $4.12 from $4.23. CL trades at $87.47 with a P/E ratio of 34.6 and a gross profit margin of 60%. Other analysts have maintained positive outlooks, with RBC and UBS setting higher price targets.

$CLMedAI 8/10

Colgate-Palmolive Explores Sale Of Softsoap, Irish Spring, Speed Stick Brands: Report

Colgate-Palmolive (CL) is exploring the sale of brands like Softsoap, Irish Spring, and Speed Stick, potentially fetching over $1 billion. The company is working with Goldman Sachs (GS) on the divestiture. Personal care accounted for 17% of CL's 2025 net sales, which totaled $20.38 billion. The move is part of a broader productivity and restructuring program aimed at generating annual pre-tax savings of $200 million to $300 million by 2028.

$CLMedAI 8/10

Colgate-Palmolive reportedly weighs US$1B personal care offload.

Colgate-Palmolive is reportedly considering the sale of select mass-market personal care brands, including Softsoap, Irish Spring, and Speed Stick, for over $1 billion. The company is working with Goldman Sachs on the potential divestment to focus on higher-margin businesses amid North American competition. Personal care accounted for 17% of its 2025 net sales of $20.38 billion.

$CLMed

CL Stock Alert: Colgate-Palmolive Reportedly Considers $1 Billion Brand Sale

Colgate-Palmolive (CL) is reportedly exploring the sale of non-core personal care brands, valued at over $1 billion, with Goldman Sachs' advisory. The move aims to reallocate capital toward higher-growth segments. CL shares are down 12% year-to-date, trading below major moving averages, but offer a 2.44% dividend yield. Institutional investors remain bullish, and the consensus rating is 'Moderate Buy' with a mean price target of $160.

$CLMedAI 8/10

Colgate-Palmolive Seeks Value Through Portfolio Reshaping

Colgate-Palmolive (NYSE:CL) is exploring the sale of mass-market personal care brands, including Softsoap, Irish Spring, and Speed Stick, potentially generating over $1 billion. The move aims to simplify its portfolio and focus on higher-growth areas like oral care and pet nutrition, amid competitive pressure in North America. The company reported a 4.9% increase in net sales, but organic sales in North America declined 3%. Proceeds could be used for debt reduction, share repurchases, or acquisi